Overview

A Clinical Study to Evaluate the Safety and the Pharmacokinetics of UI068 in Healthy Adult Volunteers Under Fed Conditions

Status:
Completed
Trial end date:
2023-08-29
Target enrollment:
Participant gender:
Summary
This study was open-label, randomized, fed, single-dose, 2-groups, 2 periods, crossover designe to compare the safety and pharmacokinetics of UI068 and co-administration of UIC202205 and UIC202206.
Phase:
Phase 1
Details
Lead Sponsor:
Korea United Pharm. Inc.